From the classical studies demonstrating improved renal and cardiovascular outcomes on reducing proteinuria with ACE inhibitors in diabetic nephropathy [62] to more recent studies of similar improvements noted in both non-diabetic kidney disease [63,64] and diabetic nephropathy [65,66,67] treated with SGLT-2 inhibitors, the significance of reducing proteinuria remains widely appreciated by nephrologists, though not always by our non-nephrologist colleagues. Here, ACE is linked to diabetic kidney disease.